Jennison Associates
CRVS icon

Jennison Associates’s Corvus Pharmaceuticals CRVS Stock Holding History

Jennison Associates’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-466,724
Closed -$4.83M – 667
2017
Q4 		$4.83M Sell
466,724
-425,927
-48% -$5.45M ﹤0.01% 497
2017
Q3 		$14.2M Sell
892,651
-126,362
-12% -$1.75M 0.01% 447
2017
Q2 		$12.3M Buy
1,019,013
+475,164
+87% +$5.07M 0.01% 458
2017
Q1 		$11.3M Sell
543,849
-26,352
-5% -$413K 0.01% 481
2016
Q4 		$8.15M Buy
570,201
+874
+0.2% +$13.3K 0.01% 493
2016
Q3 		$9.37M Sell
569,327
-1,154
-0.2% -$16.6K 0.01% 479
2016
Q2 		$8.07M Buy
570,481
+106,349
+23% +$1.44M 0.01% 479
2016
Q1 		$6.58M Buy
+464,132
New +$6.66M 0.01% 479

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Jennison Associates's CRVS Position: Q1 2018 in Review

Jennison Associates sold out of Corvus Pharmaceuticals (CRVS) in Q1 2018, closing a stake of 466,724 shares — an estimated $4.83M sold.

Jennison Associates first reported a position in CRVS in Q1 2016 and held it in 8 quarters. The position peaked at $14.2M in Q3 2017. 55 funds tracked by Wall St. Rank hold CRVS as of Q1 2018.

  • Jennison Associates reported no remaining Corvus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Jennison Associates sold 466,724 Corvus Pharmaceuticals shares in Q1 2018, an estimated $4.83M.
  • Jennison Associates first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 8 quarters.
  • Jennison Associates's Corvus Pharmaceuticals position peaked at $14.2M in Q3 2017.
  • 55 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2018.

Based on Jennison Associates's 13F filing for Q1 2018, filed 20 Apr 2018.